HTTIF.US HighTide Therapeutics, Inc.
- Market cap
- USD 236M
- P/E
- -
- P/B
- 9.50x
- ROE
- -75.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is HTTIF.US undervalued?
Graham numberThe Graham number of HighTide Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HighTide Therapeutics, Inc. fundamental analysis
No fundamental analysis for HighTide Therapeutics, Inc. yet.
HighTide Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HighTide Therapeutics, Inc.
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obe…
Full company profileHighTide Therapeutics, Inc. financial statements
HighTide Therapeutics, Inc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -218M | -438M | -406M | -215M |
| EBITDA | -189M | -937M | -374M | -223M |
| Net Income | -190M | -939M | -382M | -232M |
| EPS | -0.37 | -1.82 | -0.74 | -0.46 |
| Balance Sheet | ||||
| Total Assets | 856M | 795M | 560M | 551M |
| Total Liabilities | 1.33B | 92.3M | 136M | 187M |
| Shareholders' Equity | -471M | 703M | 424M | 307M |
| Cash & Short-term Investments | 412M | 608M | 311M | 232M |
| Cash Flow | ||||
| Operating Cash Flow | -172M | -357M | -298M | -167M |
| Capital Expenditure | 183K | 801K | 4.29M | 74.0K |
| Free Cash Flow | -173M | -357M | -303M | -167M |
| Ratios | ||||
| ROE | - | -133.7% | -90.0% | -75.6% |
| ROA | -22.2% | -118.1% | -68.2% | -42.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
HighTide Therapeutics, Inc. dividends
HighTide Therapeutics, Inc. has not paid dividends in the last 4 fiscal years.
Who owns HighTide Therapeutics, Inc.
- Insiders 46.10%
- Institutions 0.05%
- Public & others 53.85%
- Shares outstanding 607M
- Free float 260M
HighTide Therapeutics, Inc. company profile
- Company name
- HighTide Therapeutics, Inc.
- Ticker
- HTTIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Fiscal year end
- December
- Address
- Shenzhen-Hong Kong, Shenzhen, China, 518112
- Phone
- 86 755 2662 6253
- Website
- hightidetx.com
About HighTide Therapeutics, Inc.
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disease. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTD1804 that is in preclinical trial to treat obesity; and HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.
HighTide Therapeutics, Inc. management
6- Dr. Liping LiuCEO & Executive Chairwoman · born 1970
- Ms. Meng YuCOO & Executive Director · born 1982
- Ms. Liping GaoJoint Company Secretary & Investor Relations Director · born 1981
- Dr. Filip SurmontChief Medical Officer
- Dr. Dong HanHead of Business Development
- Ms. Pik Man ChuJoint Company Secretary · born 1997